Meryx Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

Meryx General Information

Description

Developer of therapeutics intended to inhibit growth and initiate anti-tumor immunity in a range of hematologic and solid malignancies The company develops orally bioavailable inhibitors targeting receptor tyrosine kinases with the potential to both inhibit tumor growth and initiate anti-tumor immunity in a wide range of cancers such as leukemia, lung cancer, and melanoma, enabling clinicians to treat cancer and other diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 510 Meadowmont Village Circle
  • Suite 359
  • Chapel Hill, NC 27517
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Meryx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 07-Dec-2021 00.000 Completed Generating Revenue
2. Seed Round 29-Jun-2015 00.00 00.000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 29-Dec-2014 $4.65M $4.65M 000.00 Completed Pre-Clinical Trials
To view Meryx’s complete valuation and funding history, request access »

Meryx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Meryx’s complete cap table history, request access »

Meryx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutics intended to inhibit growth and initiate anti-tumor immunity in a range of hematologic and soli
Drug Discovery
Chapel Hill, NC
3 As of 2015
00.000
000000&0 00.000

000000

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostr
0000 000000000
Lexington, MA
00 As of 0000
00000
00000 0000-00-00
00000000 00000

000000

is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000000000000
Gaithersburg, MD
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Meryx Competitors (62)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cyteir Therapeutics Formerly VC-backed Lexington, MA 00 00000 00000000 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Kite Pharma Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
TScan Therapeutics Formerly VC-backed Waltham, MA 000 00000 00000000 00000
AnTolRx Venture Capital-Backed Cambridge, MA 000 00000000000 000
You’re viewing 5 of 62 competitors. Get the full list »

Meryx Patents

Meryx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3947389-A1 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019 0000000000
EP-3947389-A4 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019 0000000000
US-20220162214-A1 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019 0000000000
AU-2020256186-A1 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019 0000000000
CA-3146343-A1 Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications Pending 02-Apr-2019 C07D487/04
To view Meryx’s complete patent history, request access »

Meryx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Meryx Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Eshelman Ventures Venture Capital Minority 000 0000 000000 0
Seth Rudnick Angel (individual) Minority 000 0000 000000 0
To view Meryx’s complete investors history, request access »

Meryx FAQs

  • When was Meryx founded?

    Meryx was founded in 2013.

  • Who is the founder of Meryx?

    Stephen Frye Ph.D, H. Earp MD, and Douglas Graham Ph.D are the founders of Meryx.

  • Where is Meryx headquartered?

    Meryx is headquartered in Chapel Hill, NC.

  • What is the size of Meryx?

    Meryx has 3 total employees.

  • What industry is Meryx in?

    Meryx’s primary industry is Drug Discovery.

  • Is Meryx a private or public company?

    Meryx is a Private company.

  • What is Meryx’s current revenue?

    The current revenue for Meryx is 00000.

  • How much funding has Meryx raised over time?

    Meryx has raised $7.15M.

  • Who are Meryx’s investors?

    Eshelman Ventures and Seth Rudnick have invested in Meryx.

  • Who are Meryx’s competitors?

    Cyteir Therapeutics, NexImmune, Kite Pharma, TScan Therapeutics, and AnTolRx are some of the 62 competitors of Meryx.

  • When was Meryx acquired?

    Meryx was acquired on 07-Dec-2021.

  • Who acquired Meryx?

    Meryx was acquired by Xcovery.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »